Skip to main content
. 2013 Nov 28;8(11):e81897. doi: 10.1371/journal.pone.0081897

Figure 3. Odds ratio of EGFR-MoAbs associated FAEs versus control from randomized controlled trials of patients with cancer.

Figure 3